A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
2024 · New England Journal of Medicine · 1,494 citations
https://doi.org/10.1056/nejmoa2309000
M
Mazen Noureddin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
539
Papers
20.4K
Citations
72
h-index
222
i10-index
Mazen Noureddin is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Liver Disease Diagnosis and Treatment & Liver Disease and Transplantation & Hepatocellular Carcinoma Treatment and Prognosis. The author has an h-index of 72, co-authored 459 publications.
ORCID: 0000-0003-2127-2040Papers by this author
worksThe global burden of metabolic disease: Data from 2000 to 2019
2023 · Cell Metabolism · 703 citations
https://doi.org/10.1016/j.cmet.2023.02.003
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
2022 · The Lancet. Gastroenterology & hepatology · 595 citations
https://doi.org/10.1016/s2468-1253(22)00317-x
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2024 · New England Journal of Medicine · 373 citations
https://doi.org/10.1056/nejmoa2401755
Challenges and opportunities in NASH drug development
2023 · Nature Medicine · 315 citations
https://doi.org/10.1038/s41591-023-02242-6
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis
2021 · Journal of Hepatology · 180 citations
https://doi.org/10.1016/j.jhep.2021.11.012
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat